Table 1 Adverse events occurred post-infusion and after Selinexor maintenance
Patient | Post CT103A infusion | Grade | After Selinexor use | Grade |
|---|---|---|---|---|
Patient 1 | CRS | 2 | Loss of appetite | 2 |
Fever | 1 | Fatigue | 2 | |
Hypoxemia | 1 | Neutropenia | 3 | |
Neutropenia | 4 | Anemia | 2 | |
Lymphopenia | 4 | |||
Anemia | 2 | |||
Thrombocytopenia | 4 | |||
Hypoglobulinemia | 1 | |||
Pulmonary infection | 3 | |||
CMV reactivation | 3 | |||
Patient 2 | CRS | 1 | Loss of appetite | 1 |
Fever | 1 | Fatigue | 1 | |
Neutropenia | 4 | Diarrhea | 1 | |
Lymphopenia | 4 | Weight loss | 1 | |
Anemia | 3 | Nausea | 1 | |
Thrombocytopenia | 4 | Neutropenia | 3 | |
Elevated LDH | 1 | Anemia | 2 | |
Hypoalbuminemia | 2 | Thrombocytopenia | 1 | |
Hypoglobulinemia | 1 | |||
Hypokalemia | 2 | |||
Herpes zoster reactivation | 3 | |||
Urinary tract infection | 3 |